Hepatocellular carcinoma (HCC), a liver cancer originating from hepatocytes, is a major health concern and among the most common malignancies worldwide. Sorafenib, approved by the U.S. F.D.A., is the primary first-line treatment for patients with advanced HCC. While the preferred first-line systemic regimen for HCC is immunotherapy with Atezolizumab plus bevacizumab or Tremelimumab-actl + durvalumab, Sorafenib is still an alternative recommended regimen. While some patients with advanced HCC may benefit from Sorafenib treatment, most eventually develop resistance, leading to poor prognosis. Long noncoding RNAs (lncRNAs) have been found to play a critical role in tumorigenesis and the development of HCC, as well as other cancers. They are also key players in tumor drug resistance, though the mechanisms of lncRNAs in Sorafenib resistance in HCC remain poorly understood. This review summarizes the molecular mechanisms contributing to Sorafenib resistance in HCC with their potential correlation with lncRNAs, including the roles of transporters, receptors, cell death regulation, and other influencing factors.
肝细胞癌（HCC）是一种起源于肝细胞的肝癌，是全球主要的健康问题及最常见的恶性肿瘤之一。经美国食品药品监督管理局批准的索拉非尼是晚期HCC患者的主要一线治疗药物。尽管目前HCC首选的一线全身治疗方案为阿特珠单抗联合贝伐珠单抗或Tremelimumab-actl联合度伐利尤单抗的免疫疗法，索拉非尼仍作为推荐替代方案。虽然部分晚期HCC患者可能从索拉非尼治疗中获益，但多数患者最终会产生耐药性，导致预后不良。长链非编码RNA（lncRNA）已被证实在HCC及其他癌症的肿瘤发生发展中起关键作用，同时也是肿瘤耐药的重要调控因子，然而lncRNA在HCC索拉非尼耐药中的具体机制尚不明确。本综述系统阐述了HCC索拉非尼耐药的分子机制及其与lncRNA的潜在关联，包括转运蛋白、受体、细胞死亡调控及其他影响因素的作用。
The Emerging Role of Long Noncoding RNAs in Sorafenib Resistance Within Hepatocellular Carcinoma
肿瘤(癌症)患者之家